IGF-I/IGFBP-3 ratio: A mechanistic insight into the metabolic syndrome

Justo Sierra-Johnson, Abel Romero-Corral, Virend Somers, Francisco Lopez-Jimenez, Anders Mälarstig, Kerstin Brismar, Anders Hamsten, Rachel M. Fisher, Mai L. Hellénius

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Recent reports suggest that IGF (insulin-like growth factor)-I and IGFBP-3 (IGF-binding protein-3) have independent and opposing mechanistic effects on insulin. The aim of the present study was to assess the relationship between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. We examined 3281 subjects (1463 men and 1818 women, aged 20-49 years), otherwise healthy adults, who participated in NHANES III (Third National Health and Nutrition Examination Survey), which has released measurements of IGF-I and IGFBP-3. Insulin resistance was estimated using the computer HOMA2 (homoeostatic model assessment 2) model. The updated ATP-III (Adult Treatment Panel III) definition of the metabolic syndrome was used. We applied adjusted logistic and linear regression models. After adjusting for age and race, men and women in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. Mean values of the IGF-I/IGFBP-3 ratio decreased significantly as the number of metabolic syndrome components increased (P<0.0001, as determined by ANOVA). The area under the ROC (receiver operating characteristic) curve for detecting insulin resistance using the IGF-I/IGFBP-3 ratio was 0.760, significantly improving upon either protein alone (P=0.01). In conclusion, the IGF-I/ IGFBP-3 ratio is significantly associated with the metabolic syndrome. Calculating the ratio of these two proteins may provide insight into the metabolic syndrome clustering phenomenon.

Original languageEnglish (US)
Pages (from-to)507-512
Number of pages6
JournalClinical Science
Volume116
Issue number6
DOIs
StatePublished - Mar 2009

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Nutrition Surveys
Insulin Resistance
Linear Models
Insulin
ROC Curve
Computer Simulation
Cluster Analysis
Analysis of Variance
Proteins
Logistic Models
Therapeutics

Keywords

  • Cardiovascular disease
  • Insulin resistance
  • Insulin-like growth factor-binding protein-3 (IGFBP-3)
  • Insulin-like growth factor-I (IGF-I)
  • Metabolic syndrome
  • Third National Health and Nutrition Examination Survey (NHANES III)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sierra-Johnson, J., Romero-Corral, A., Somers, V., Lopez-Jimenez, F., Mälarstig, A., Brismar, K., ... Hellénius, M. L. (2009). IGF-I/IGFBP-3 ratio: A mechanistic insight into the metabolic syndrome. Clinical Science, 116(6), 507-512. https://doi.org/10.1042/CS20080382

IGF-I/IGFBP-3 ratio : A mechanistic insight into the metabolic syndrome. / Sierra-Johnson, Justo; Romero-Corral, Abel; Somers, Virend; Lopez-Jimenez, Francisco; Mälarstig, Anders; Brismar, Kerstin; Hamsten, Anders; Fisher, Rachel M.; Hellénius, Mai L.

In: Clinical Science, Vol. 116, No. 6, 03.2009, p. 507-512.

Research output: Contribution to journalArticle

Sierra-Johnson, J, Romero-Corral, A, Somers, V, Lopez-Jimenez, F, Mälarstig, A, Brismar, K, Hamsten, A, Fisher, RM & Hellénius, ML 2009, 'IGF-I/IGFBP-3 ratio: A mechanistic insight into the metabolic syndrome', Clinical Science, vol. 116, no. 6, pp. 507-512. https://doi.org/10.1042/CS20080382
Sierra-Johnson, Justo ; Romero-Corral, Abel ; Somers, Virend ; Lopez-Jimenez, Francisco ; Mälarstig, Anders ; Brismar, Kerstin ; Hamsten, Anders ; Fisher, Rachel M. ; Hellénius, Mai L. / IGF-I/IGFBP-3 ratio : A mechanistic insight into the metabolic syndrome. In: Clinical Science. 2009 ; Vol. 116, No. 6. pp. 507-512.
@article{b73d680415d74771ae2c27102eac9a9a,
title = "IGF-I/IGFBP-3 ratio: A mechanistic insight into the metabolic syndrome",
abstract = "Recent reports suggest that IGF (insulin-like growth factor)-I and IGFBP-3 (IGF-binding protein-3) have independent and opposing mechanistic effects on insulin. The aim of the present study was to assess the relationship between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. We examined 3281 subjects (1463 men and 1818 women, aged 20-49 years), otherwise healthy adults, who participated in NHANES III (Third National Health and Nutrition Examination Survey), which has released measurements of IGF-I and IGFBP-3. Insulin resistance was estimated using the computer HOMA2 (homoeostatic model assessment 2) model. The updated ATP-III (Adult Treatment Panel III) definition of the metabolic syndrome was used. We applied adjusted logistic and linear regression models. After adjusting for age and race, men and women in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. Mean values of the IGF-I/IGFBP-3 ratio decreased significantly as the number of metabolic syndrome components increased (P<0.0001, as determined by ANOVA). The area under the ROC (receiver operating characteristic) curve for detecting insulin resistance using the IGF-I/IGFBP-3 ratio was 0.760, significantly improving upon either protein alone (P=0.01). In conclusion, the IGF-I/ IGFBP-3 ratio is significantly associated with the metabolic syndrome. Calculating the ratio of these two proteins may provide insight into the metabolic syndrome clustering phenomenon.",
keywords = "Cardiovascular disease, Insulin resistance, Insulin-like growth factor-binding protein-3 (IGFBP-3), Insulin-like growth factor-I (IGF-I), Metabolic syndrome, Third National Health and Nutrition Examination Survey (NHANES III)",
author = "Justo Sierra-Johnson and Abel Romero-Corral and Virend Somers and Francisco Lopez-Jimenez and Anders M{\"a}larstig and Kerstin Brismar and Anders Hamsten and Fisher, {Rachel M.} and Hell{\'e}nius, {Mai L.}",
year = "2009",
month = "3",
doi = "10.1042/CS20080382",
language = "English (US)",
volume = "116",
pages = "507--512",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "6",

}

TY - JOUR

T1 - IGF-I/IGFBP-3 ratio

T2 - A mechanistic insight into the metabolic syndrome

AU - Sierra-Johnson, Justo

AU - Romero-Corral, Abel

AU - Somers, Virend

AU - Lopez-Jimenez, Francisco

AU - Mälarstig, Anders

AU - Brismar, Kerstin

AU - Hamsten, Anders

AU - Fisher, Rachel M.

AU - Hellénius, Mai L.

PY - 2009/3

Y1 - 2009/3

N2 - Recent reports suggest that IGF (insulin-like growth factor)-I and IGFBP-3 (IGF-binding protein-3) have independent and opposing mechanistic effects on insulin. The aim of the present study was to assess the relationship between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. We examined 3281 subjects (1463 men and 1818 women, aged 20-49 years), otherwise healthy adults, who participated in NHANES III (Third National Health and Nutrition Examination Survey), which has released measurements of IGF-I and IGFBP-3. Insulin resistance was estimated using the computer HOMA2 (homoeostatic model assessment 2) model. The updated ATP-III (Adult Treatment Panel III) definition of the metabolic syndrome was used. We applied adjusted logistic and linear regression models. After adjusting for age and race, men and women in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. Mean values of the IGF-I/IGFBP-3 ratio decreased significantly as the number of metabolic syndrome components increased (P<0.0001, as determined by ANOVA). The area under the ROC (receiver operating characteristic) curve for detecting insulin resistance using the IGF-I/IGFBP-3 ratio was 0.760, significantly improving upon either protein alone (P=0.01). In conclusion, the IGF-I/ IGFBP-3 ratio is significantly associated with the metabolic syndrome. Calculating the ratio of these two proteins may provide insight into the metabolic syndrome clustering phenomenon.

AB - Recent reports suggest that IGF (insulin-like growth factor)-I and IGFBP-3 (IGF-binding protein-3) have independent and opposing mechanistic effects on insulin. The aim of the present study was to assess the relationship between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. We examined 3281 subjects (1463 men and 1818 women, aged 20-49 years), otherwise healthy adults, who participated in NHANES III (Third National Health and Nutrition Examination Survey), which has released measurements of IGF-I and IGFBP-3. Insulin resistance was estimated using the computer HOMA2 (homoeostatic model assessment 2) model. The updated ATP-III (Adult Treatment Panel III) definition of the metabolic syndrome was used. We applied adjusted logistic and linear regression models. After adjusting for age and race, men and women in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. Mean values of the IGF-I/IGFBP-3 ratio decreased significantly as the number of metabolic syndrome components increased (P<0.0001, as determined by ANOVA). The area under the ROC (receiver operating characteristic) curve for detecting insulin resistance using the IGF-I/IGFBP-3 ratio was 0.760, significantly improving upon either protein alone (P=0.01). In conclusion, the IGF-I/ IGFBP-3 ratio is significantly associated with the metabolic syndrome. Calculating the ratio of these two proteins may provide insight into the metabolic syndrome clustering phenomenon.

KW - Cardiovascular disease

KW - Insulin resistance

KW - Insulin-like growth factor-binding protein-3 (IGFBP-3)

KW - Insulin-like growth factor-I (IGF-I)

KW - Metabolic syndrome

KW - Third National Health and Nutrition Examination Survey (NHANES III)

UR - http://www.scopus.com/inward/record.url?scp=65549106138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549106138&partnerID=8YFLogxK

U2 - 10.1042/CS20080382

DO - 10.1042/CS20080382

M3 - Article

C2 - 18816247

AN - SCOPUS:65549106138

VL - 116

SP - 507

EP - 512

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 6

ER -